ReviewCurrent oncology (Toronto, Ont.)2021
Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic.
Review in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Artificial intelligence integrated multi-omics and multimodal studies promote the efficacy of neoadjuvant chemotherapy in breast cancer: opportunities, challenges, and future perspectives.Breast cancer research : BCR · 2026Review
- The impact of the COVID-19 pandemic on breast cancer screening, treatment, and overall survival.Breast cancer research and treatment · 2026Article
- SanHuang decoction may suppress breast cancer by regulating M1 macrophage polarization via NF-κB signaling pathway:Translational cancer research · 2026Article
- The association between body mass index and neoadjuvant chemotherapy response in patients with breast cancer.Breast cancer research : BCR · 2025Article
- Revealing the Role of Beesioside O fromInternational journal of molecular sciences · 2025Article
- Systematic elucidation of the effective constituents and potential mechanisms ofFrontiers in plant science · 2025Article
- Rare Giant Pure Yolk Sac Tumor Originating from Cryptorchidism in an Adult.Cancer management and research · 2025Article
- Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery.Annals of surgical oncology · 2024Article
- Review
- Lipid metabolism as a target for cancer drug resistance: progress and prospects.Frontiers in pharmacology · 2023Review
- Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort Study.Clinical breast cancer · 2022Article
- The Mechanism of Warburg Effect-Induced Chemoresistance in Cancer.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Practice and behaviour change in healthcare is complex, and requires a set of critical steps that would be needed to implement and sustain the change. Neoadjuvant chemotherapy for breast cancer is traditionally used for locally advanced disease and is primarily advantageous for surgical downstaging purposes. However, it does also offer patients with certain biologic subtypes such as the triple negative or Her2 positive breast cancers the opportunity to improve survival, even in early stage disease. During the height of the pandemic, an opportunity and motivation for the increased use of neoadjuvant therapy in breast cancer was identified. This paper describes the conditions that have supported this practice change at the provider and institutional levels. We also include our own institutional algorithm based on tumor biology and extent of disease that have guided our decisions on breast cancer management during the pandemic. Our processes can be adapted by other institutions and breast oncology practices in accordance with local conditions and resources, during and beyond the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.